Clinical Trial Update: Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating venetoclax, ponatinib, and dexamethasone in patients with BCR-ABL1 positive Philadelphia chromosome positive relapsed or refractory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Iclusig (ponatinib)
• Venclexta (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-05-08